163 related articles for article (PubMed ID: 38216214)
1. Inclisiran: Government's strategy to promote cholesterol lowering drug after Brexit was "spectacular failure," says insider.
Cohen D; McCartney M
BMJ; 2024 Jan; 384():q90. PubMed ID: 38216214
[No Abstract] [Full Text] [Related]
2. GP leaders advise practices not to prescribe cholesterol lowering drug inclisiran.
Iacobucci G
BMJ; 2023 Aug; 382():1757. PubMed ID: 37527847
[No Abstract] [Full Text] [Related]
3. Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering.
Soffer D; Stoekenbroek R; Plakogiannis R
J Clin Lipidol; 2022; 16(5):574-582. PubMed ID: 35909047
[TBL] [Abstract][Full Text] [Related]
4. UK deal over inclisiran.
Byrne P; Cullinan J; Mintzes B; Smith SM
BMJ; 2020 Feb; 368():m579. PubMed ID: 32071100
[No Abstract] [Full Text] [Related]
5. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol.
Samuel E; Watford M; Egolum UO; Ombengi DN; Ling H; Cates DW
Ann Pharmacother; 2023 Mar; 57(3):317-324. PubMed ID: 35775133
[TBL] [Abstract][Full Text] [Related]
6. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Ray KK; Wright RS; Kallend D; Koenig W; Leiter LA; Raal FJ; Bisch JA; Richardson T; Jaros M; Wijngaard PLJ; Kastelein JJP;
N Engl J Med; 2020 Apr; 382(16):1507-1519. PubMed ID: 32187462
[TBL] [Abstract][Full Text] [Related]
7. Inclisiran: A Review in Hypercholesterolemia.
Frampton JE
Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996
[TBL] [Abstract][Full Text] [Related]
8. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].
Scheen AJ; Wallemacq C; Lancellotti P
Rev Med Liege; 2022 Dec; 77(12):745-751. PubMed ID: 36484754
[TBL] [Abstract][Full Text] [Related]
9. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U
Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965
[TBL] [Abstract][Full Text] [Related]
11. [Inclisiran - a new era in lipid-lowering therapy].
Voevoda MI; Gurevich VS; Ezhov MV; Sergienko IV
Kardiologiia; 2022 Jun; 62(6):57-62. PubMed ID: 35834343
[TBL] [Abstract][Full Text] [Related]
12. Inclisiran in dyslipidemia.
Kosmas CE; Muñoz Estrella A; Sourlas A; Pantou D
Drugs Today (Barc); 2021 May; 57(5):311-319. PubMed ID: 34061126
[TBL] [Abstract][Full Text] [Related]
13. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
Sinning D; Landmesser U
Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease.
Tomlinson B; Chow E; Chan P; Lam CWK
Expert Opin Drug Metab Toxicol; 2021 Dec; 17(12):1353-1361. PubMed ID: 35025707
[TBL] [Abstract][Full Text] [Related]
15. Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus.
Rakocevic J; Dobric M; Vucic R; Furtula M; Zaletel I; Milutinovic K; Ilijevski A; Borovic ML; Tomasevic M; Bajcetic M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983086
[TBL] [Abstract][Full Text] [Related]
16. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
Ray KK; Landmesser U; Leiter LA; Kallend D; Dufour R; Karakas M; Hall T; Troquay RP; Turner T; Visseren FL; Wijngaard P; Wright RS; Kastelein JJ
N Engl J Med; 2017 Apr; 376(15):1430-1440. PubMed ID: 28306389
[TBL] [Abstract][Full Text] [Related]
17. Inclisiran-A Revolutionary Addition to a Cholesterol-Lowering Therapy.
Dec A; Niemiec A; Wojciechowska E; Maligłówka M; Bułdak Ł; Bołdys A; Okopień B
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047830
[TBL] [Abstract][Full Text] [Related]
18. Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
Hovingh GK; Lepor NE; Kallend D; Stoekenbroek RM; Wijngaard PLJ; Raal FJ
Circulation; 2020 Jun; 141(22):1829-1831. PubMed ID: 32479195
[No Abstract] [Full Text] [Related]
19. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.
Ray KK; Kallend D; Leiter LA; Raal FJ; Koenig W; Jaros MJ; Schwartz GG; Landmesser U; Garcia Conde L; Wright RS;
Eur Heart J; 2022 Dec; 43(48):5047-5057. PubMed ID: 36331315
[TBL] [Abstract][Full Text] [Related]
20. Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of siRNA Therapies for Prevention?
Ballantyne CM; Minhas AMK; Orringer CE
J Am Coll Cardiol; 2023 Dec; 82(24):2262-2264. PubMed ID: 38057067
[No Abstract] [Full Text] [Related]
[Next] [New Search]
